<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Opsoclonus-myoclonus-ataxia syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Opsoclonus-myoclonus-ataxia syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Opsoclonus-myoclonus-ataxia syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Josep Dalmau, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Myrna R Rosenfeld, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H24048016"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Opsoclonus-myoclonus-ataxia syndrome (OMAS), also known as opsoclonus-myoclonus, is a rare and debilitating acquired nervous system disorder characterized by opsoclonus, diffuse or focal body myoclonus, and truncal titubation with or without ataxia and other cerebellar signs.</p><p>OMAS occurs most commonly in young children, either as a paraneoplastic disorder in association with neuroblastoma or as an apparent postviral syndrome. In adults, OMAS can be paraneoplastic or idiopathic. In both children and adults, therapy consists of treatment of the underlying tumor, if present, and immune suppression.</p><p>This topic discusses OMAS in children and adults. Approaches to the evaluation and diagnosis of ataxia, myoclonus, and other paraneoplastic disorders of the nervous system are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6465.html" rel="external">"Approach to the child with acute ataxia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4885.html" rel="external">"Classification and evaluation of myoclonus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a>.)</p><p></p><p class="headingAnchor" id="H24047689"><span class="h1">PEDIATRIC SYNDROME</span></p><p class="headingAnchor" id="H990442608"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>OMAS is rare; one prospective study in the United Kingdom estimated an incidence of 0.18 cases per million per year [<a href="#rid1">1</a>]. OMAS affects mainly young children with a mean age of 1.5 to 2 years [<a href="#rid1">1-4</a>].</p><p class="headingAnchor" id="H24048187"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>OMAS is thought to be an acquired immune-mediated disorder, although a specific and reproducible biomarker remains elusive.</p><p>Approximately half of cases in children are paraneoplastic in association with neuroblastoma, a childhood neoplasm arising from primitive sympathetic ganglion cells. Neural antigens expressed by the tumor cells are the presumed basis for an adaptive immune response in the central nervous system. Overall, only a small minority of patients with neuroblastoma (2 to 3 percent) develop OMAS [<a href="#rid5">5,6</a>]. Rarely, pediatric OMAS has been reported with other tumors, such as ovarian teratoma. (See  <a class="medical medical_review" href="/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma"</a>.)</p><p>A role for antibody-mediated mechanisms is supported by studies showing expansion of CD19+ B cells in the cerebrospinal fluid (CSF) of children with OMAS [<a href="#rid7">7</a>] and the presence of CSF oligoclonal bands in more than one-half of untreated patients [<a href="#rid8">8</a>]. Autoimmune responses to a variety of well-known neuronal autoantigens or uncharacterized neuronal targets have been demonstrated [<a href="#rid9">9-13</a>], but specific pathogenic autoantibodies have yet to be identified.</p><p>Nonparaneoplastic OMAS in children is believed to have a para-infectious origin in some cases. Pathogens that have been implicated include hepatitis C [<a href="#rid14">14</a>], Lyme disease [<a href="#rid15">15</a>], Epstein-Barr virus [<a href="#rid16">16,17</a>], poststreptococcal infection [<a href="#rid18">18</a>], human immunodeficiency virus (HIV; possibly with immune reconstitution inflammatory syndrome) [<a href="#rid19">19</a>], Coxsackie B3 [<a href="#rid20">20</a>], mycoplasma pneumoniae [<a href="#rid21">21</a>], and rotavirus [<a href="#rid1">1</a>]. In idiopathic cases of OMAS, a postviral origin is sometimes inferred based upon a suggestive history of a viral prodrome [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H24048201"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Children with OMAS usually present with subacute ataxia manifesting as gait imbalance, staggering, falls, and/or a refusal to walk. Symptoms usually progress over days to weeks [<a href="#rid2">2,22,23</a>]. Parents often describe a viral prodrome, even in cases that are found to be paraneoplastic [<a href="#rid2">2,4</a>]. Common prodromal symptoms include crying and irritability, cough, lethargy, fever, and vomiting.</p><p>Myoclonus of the limbs and trunk, tremor, and hypotonia may develop at the same time as the ataxia or subsequently [<a href="#rid4">4</a>]. Behavioral changes (often described as irritability, inconsolable crying) and moderate to severe sleep disturbances are common. Many children lose previously acquired speech and language skills [<a href="#rid24">24</a>].</p><p>Most patients also have opsoclonus, which is defined as spontaneous, involuntary, arrhythmic, conjugate, multidirectional saccades occurring in all directions of gaze without a saccadic interval. Although opsoclonus is characteristic of the disorder, it may not be present at initial evaluation and can be transient and difficult to see during examination [<a href="#rid1">1</a>]. The absence of this most distinctive finding can delay diagnosis of OMAS, particularly if the patient does not have a known neuroblastoma. Examination of home videos taken by parents or caregivers can be helpful.</p><p>Symptoms of OMAS precede the diagnosis of neuroblastoma in approximately one-half of patients. Symptoms usually fluctuate in severity and may have a prolonged course. In a series of 356 children with OMAS seen at a single referral center in the United States, the median time to diagnosis was 2.1 and 3.0 months for children with and without neuroblastoma, respectively [<a href="#rid4">4</a>]. Approximately 50 percent were diagnosed within the first month of symptoms, one-quarter to one-third had symptoms for 1 to 3 months, and the remaining patients had symptoms for greater than 3 months before diagnosis.</p><p>Neuroimaging is normal in most children with acute OMAS [<a href="#rid1">1,25</a>]. Long-term follow-up may demonstrate cerebellar atrophy and cortical volume loss [<a href="#rid26">26</a>].</p><p>CSF findings in OMAS are nonspecific. Approximately 15 percent of children have a mild lymphocytic pleocytosis and over half have positive oligoclonal bands [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H24048209"><span class="h2">Diagnosis in children</span><span class="headingEndMark"> — </span>OMAS is a clinical diagnosis based on characteristic clinical features and exclusion of alternative etiologies. There are no biomarkers for the disorder aside from the presence of a peripheral neuroblastic tumor in approximately half of children.</p><p>Based on expert panel recommendations, the diagnosis may be made when at least three out of four clinical features are present, in the appropriate clinical context: opsoclonus, ataxia or myoclonus, behavior change or sleep disturbance, and neuroblastoma [<a href="#rid24">24</a>]. (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H2995675350"><span class="h3">Clinical evaluation</span><span class="headingEndMark"> — </span>All children presenting with acute ataxia with or without myoclonus and behavioral changes should have laboratory testing and review of medications to exclude a toxic-metabolic encephalopathy, including a hyperosmolar state, liver disease, and intoxications. Neuroimaging to exclude a structural abnormality and lumbar puncture, unless contraindicated, should also be performed in most patients unless the etiology is readily apparent based on initial evaluation. (See  <a class="medical medical_review" href="/d/html/6154.html" rel="external">"Acute toxic-metabolic encephalopathy in children", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/d/html/6465.html" rel="external">"Approach to the child with acute ataxia"</a>.)</p><p>When OMAS is suspected, testing recommended by an expert consensus panel includes the following [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood tests</strong> – Complete blood count, erythrocyte sedimentation rate, electrolytes, blood urea nitrogen, creatinine, uric acid, lactate, C-reactive protein, liver function tests, glucose, clotting studies (international normalized ratio and partial thromboplastin time), quantitative immunoglobulins (paired with CSF for calculation of IgG and albumin synthesis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection screening</strong> – May include testing for herpes viruses (cytomegalovirus [CMV], Epstein-Barr virus [EBV], varicella-zoster virus [VZV], human herpes virus 6 [HHV-6]), West Nile virus, adenovirus, enterovirus, and influenza as clinically indicated</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimaging</strong> – Contrast-enhanced brain magnetic resonance imaging (MRI) to exclude a focal lesion in the posterior fossa and other structural abnormalities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebrospinal fluid (CSF)</strong> – Cell count, protein level, glucose, lactate, IgG and albumin synthesis index (paired with blood sample), oligoclonal bands (paired with serum), and infectious studies as clinically indicated</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for neuroblastoma </strong>–<strong> </strong>Laboratories and imaging are reviewed below (see <a class="local">'Evaluation for neuroblastoma'</a> below)</p><p></p><p>We do not suggest paraneoplastic antibody panel testing in serum or CSF in most cases, as specific paraneoplastic biomarkers have not been identified for OMAS when associated with neuroblastoma. While children with paraneoplastic OMAS have a higher frequency of other paraneoplastic antibodies (including anti-Hu antibodies) than healthy controls, the sensitivity and specificity are low, and autoantibody screening in this population is not clinically useful [<a href="#rid1">1,6,27</a>].</p><p class="headingAnchor" id="H6266312"><span class="h3">Evaluation for neuroblastoma</span><span class="headingEndMark"> — </span>All children presenting with OMAS must be evaluated for neuroblastoma [<a href="#rid24">24,28</a>]. There are no clinical features of OMAS that distinguish children with and without an occult tumor [<a href="#rid4">4,24</a>]. A screening protocol includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Chest, abdominal, and pelvic MRI</p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA)</p><p class="bulletIndent1"><span class="glyph">●</span><sup>123</sup>I-metaiodobenzylguanidine (MIBG, iobenguane I-123) scan if MRI results are unrevealing (also used for tumor staging and follow-up if positive)</p><p></p><p>When negative, the evaluation should be repeated after several months [<a href="#rid29">29</a>]. The evaluation of children with possible neuroblastoma is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma"</a>.)</p><p class="headingAnchor" id="H523058473"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>Early in its course, the differential diagnosis of OMAS is the same as that for any child presenting with acute ataxia. Life-threatening causes (eg, posterior fossa tumors, intracranial hemorrhage, stroke, central nervous system infection, acute cerebellitis) should be considered, in addition to more common diagnoses such as acute cerebellar ataxia, drug intoxication, Guillain-Barré syndrome, and migraine-related disorders  (<a class="graphic graphic_algorithm graphicRef77260" href="/d/graphic/77260.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef79383" href="/d/graphic/79383.html" rel="external">table 1</a>). This evaluation is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6465.html" rel="external">"Approach to the child with acute ataxia"</a>.)</p><p>In the setting of fever, opsoclonus and ataxia may be manifestations of acute infectious encephalitis or meningitis. In endemic regions, more rare pathogens to consider in association with opsoclonus include scrub typhus, mumps, and tuberculous meningitis [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/6206.html" rel="external">"Acute cerebellar ataxia in children", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6042.html" rel="external">"Acute viral encephalitis in children: Clinical manifestations and diagnosis"</a>.)</p><p>Among children without evidence of structural disease or acute infection who are subsequently diagnosed with OMAS, the most common misdiagnoses are acute cerebellar ataxia and Guillain-Barré syndrome [<a href="#rid1">1,31</a>]. (See  <a class="medical medical_review" href="/d/html/6206.html" rel="external">"Acute cerebellar ataxia in children"</a> and  <a class="medical medical_review" href="/d/html/6235.html" rel="external">"Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H24048217"><span class="h2">Management</span><span class="headingEndMark"> — </span>Immune suppression is the primary treatment for OMAS in both paraneoplastic and nonparaneoplastic cases, based on the presumed autoimmune etiology, the rarity of spontaneous remissions, and the disabling nature of the disorder in many children [<a href="#rid24">24</a>]. Early initiation of immunosuppressive therapy (eg, within two weeks of diagnosis) is believed to be associated with improved outcomes [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H441193930"><span class="h3">Tumor-directed therapy</span><span class="headingEndMark"> — </span>Most children with neuroblastoma-associated OMAS have low-risk, nonmetastatic disease, and surgery is the primary oncologic therapy. Risk stratification is based on patient age, stage, pathology, and molecular genetic factors. The treatment and prognosis of neuroblastoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/5203.html" rel="external">"Treatment and prognosis of neuroblastoma"</a>.)</p><p>Despite favorable oncologic prognosis, definitive tumor treatment does not appear to improve neurologic outcomes, and children require additional OMAS-directed therapy to achieve sustained improvement [<a href="#rid2">2,33,34</a>]. Immune therapies should be initiated as soon as possible upon recognition of OMAS, in parallel with the oncologic evaluation and in coordination with the surgical team. If a delay in surgery is anticipated, initial doses of immune suppression may be given before tumor resection [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H2421059274"><span class="h3">Approach to immune suppression</span><span class="headingEndMark"> — </span>We suggest an initial regimen of glucocorticoids plus intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) in most patients, rather than glucocorticoids alone  (<a class="graphic graphic_algorithm graphicRef140814" href="/d/graphic/140814.html" rel="external">algorithm 2</a>). Reasonable alternative agents used at some centers include corticotropin (ACTH) instead of glucocorticoids and plasma exchange instead of IVIG [<a href="#rid24">24</a>]. We suggest add-on therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in children with an insufficient response in the first four to eight weeks of initial therapy; some experts favor even earlier use, at the time of diagnosis [<a href="#rid24">24</a>].</p><p>The short-term benefit of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> was demonstrated by a multicenter open-label trial in which 53 children with neuroblastoma-associated OMAS were randomly assigned to receive risk-adapted chemotherapy and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> with or without IVIG [<a href="#rid35">35</a>]. Chemotherapy consisted of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> in the majority of patients according to the Children’s Oncology Group (COG) protocol. All patients received prednisone 2 mg/kg/day in two divided doses for a minimum of two months; a slow taper could be initiated thereafter based on clinical response. IVIG was given monthly for the first six cycles (1 g/kg/day on two consecutive days for cycle 1, then 1 g/kg on day 1 of cycles 2 through 6), then 1 g/kg on day 1 of cycles 8, 10, and 12. Response was determined using an OMAS severity scale administered at two, six, and 12 months; responders were those with partial or complete improvement and no subsequent progression. Over 12 months of therapy, the proportion of responders was higher when IVIG was added to the treatment regimen (81 versus 41 percent; odds ratio [OR] 6.1, 95% CI 1.5-25.1), and adverse effects were similar between groups. Twelve patients in the standard care arm (44 percent) crossed over and received IVIG due to nonresponse within the first year (median 144 days). Long-term follow-up is ongoing.</p><p>There is limited evidence to support the optimal timing and efficacy of other add-on therapies, and treatment decisions should be individualized [<a href="#rid24">24,36-46</a>]. If a stepwise approach is chosen initially, there should be a low threshold for addition of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> for patients with an inadequate response to glucocorticoids and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> by four to eight weeks  (<a class="graphic graphic_algorithm graphicRef140814" href="/d/graphic/140814.html" rel="external">algorithm 2</a>) [<a href="#rid24">24</a>]. In either case, rituximab is generally favored over cyclophosphamide based on toxicity profiles, unless chemotherapy is indicated for oncologic reasons.</p><p>The added value of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> as initial therapy in all patients is uncertain. A retrospective chart review of children with neuroblastoma-associated OMAS concluded that early use of rituximab (within three months of diagnosis) was associated with decreased risk of relapse [<a href="#rid47">47</a>]. However, another retrospective review of OMAS with and without neuroblastoma suggested that early rituximab permitted a reduction in the duration of glucocorticoid and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> therapy but did not appear to impact relapse rate [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H2872639772"><span class="h3">Administration of specific agents</span><span class="headingEndMark"> — </span>Dosing and monitoring of immune suppression is individualized and may be influenced by institutional protocols. Reasonable regimens reviewed by the International OMAS Study Group in 2022 are included below [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H3949633580"><span class="h4">Glucocorticoids</span><span class="headingEndMark"> — </span>Both intravenous (IV) and oral steroids as well as pulsed and daily regimens have been studied. ACTH is generally reserved for second-line therapy because it is less convenient and often more expensive. The most common regimens are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulsed oral </strong><strong>dexamethasone</strong> – <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">Dexamethasone</a> 20 mg/m<sup>2</sup>/day orally in two divided doses on three consecutive days, defined as one pulse. Pulses are repeated every three to four weeks for 12 pulses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulsed IV </strong><strong>methylprednisolone</strong> – <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">Methylprednisolone</a> IV 30 mg/kg/day for three to five days, defined as one pulse. Pulses are repeated monthly for 6 to 12 months. Alternatively, the first pulse is followed by oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> starting at 1 to 2 mg/kg/day and gradually tapered over 6 to 12 months.</p><p></p><p>High-dose glucocorticoids have multiple potential side effects including irritability, hypertension, hyperglycemia, weight gain, infections, osteopenia, and an adverse impact on growth and stature. Growth impairment and other effects may be lessened by pulsed dosing. Side effects, safety monitoring, and growth implications are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/5832.html" rel="external">"Causes of short stature", section on 'Glucocorticoid therapy'</a>.)</p><p class="headingAnchor" id="H4074908222"><span class="h4">Intravenous immune globulin (IVIG)</span><span class="headingEndMark"> — </span>A typical regimen of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> is 2 g/kg over two to five days followed by 1 to 2 g/kg every four weeks for up to 12 months [<a href="#rid24">24</a>]. Administration and toxicities of IVIG are reviewed separately. (See  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a> and  <a class="medical medical_review" href="/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects"</a>.)</p><p class="headingAnchor" id="H1982183534"><span class="h4">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is a chimeric anti-CD20 monoclonal antibody that depletes B cell lymphocytes. Specific rituximab regimens vary by center, and there is no evidence of differences in efficacy or toxicity. Example regimens include [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> 375 mg/m<sup>2</sup>/dose for four weekly doses</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> 500 mg/m<sup>2</sup>/dose for two doses, 10 to 14 days apart</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> 750 mg/m<sup>2</sup>/dose for 2 doses, 14 days apart</p><p></p><p><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is usually well tolerated but carries risks of hypersensitivity, leukopenia, and hypogammaglobulinemia resulting in serious infections. Allergic or infusion reactions may occur, and clinicians should follow institutional protocols for premedication, administration, and monitoring. Serologic testing for hepatitis B, hepatitis C, and HIV should be done prior to treatment due to risk of reactivation. Prophylaxis against pneumocystis pneumonia is usually recommended in children, although practice varies. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H3988257926"><span class="h4">Cyclophosphamide</span><span class="headingEndMark"> — </span>When used upfront or as escalating add-on therapy, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is typically given as pulsed IV therapy (500 to 750 mg/m<sup>2</sup> for patients weighing ≥10 kg) once every four weeks for three to six doses [<a href="#rid24">24</a>]. Important side effects and risks include nausea, vomiting, hair loss, myelosuppression, infections, hemorrhagic cystitis, infertility, and secondary malignancies. Patients require close monitoring of kidney function and blood counts, cystitis prophylaxis, pneumocystis pneumonia prophylaxis, and appropriate immunizations and other precautionary measures.</p><p class="headingAnchor" id="H693658522"><span class="h3">Monitoring and relapse</span><span class="headingEndMark"> — </span>The goal of initial immune suppression is to achieve maximal clinical response and sustained remission. Function should be assessed serially in multiple domains, including stance and gait, arm/hand function, opsoclonus, mood/behavior, and speech. Clinicians should have a low threshold to start add-on therapy at four to eight weeks if symptoms have not improved significantly with initial therapy or in patients who develop steroid toxicities. (See <a class="local">'Approach to immune suppression'</a> above.)</p><p>Optimal duration of initial treatment is not known, but expert consensus favors a goal of clinical remission and up to a year of immune suppression before de-escalation of therapy [<a href="#rid24">24</a>]. Clinical remission is defined as normalization of walking and arm/hand function and resolution of opsoclonus; any residual abnormalities in mood, behavior, and speech should be mild.</p><p>Neurologic relapses may occur in up to half of patients. Worsening may be seen during steroid withdrawal or with intercurrent infections [<a href="#rid2">2,39</a>]. Patients with suspected relapse should be re-evaluated for acute and reversible causes as well as for tumor recurrence if clinically indicated. (See <a class="local">'Clinical evaluation'</a> above.)</p><p>Treatment of relapse is individualized based on severity of symptoms and treatment history. Patients who worsen during glucocorticoid tapering may respond to higher doses or reinstitution of pulsed therapies for several months. For patients who relapse after previously receiving <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, some experts suggest checking a B cell (CD19) count to inform decisions about restarting rituximab; if B cells are fully suppressed at the time of relapse, additional rituximab is unlikely to be helpful [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1862849809"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>The neurologic prognosis of OMAS is guarded. Among different case series, motor symptoms appear to improve or resolve in approximately 60 percent of patients during initial treatment [<a href="#rid3">3,36,38</a>]. However, regardless of pathogenesis, approximately 60 to 80 percent of patients have residual behavioral abnormalities or psychomotor retardation that sometimes become increasingly problematic later in life [<a href="#rid2">2,3,32,36,40,48,49</a>].</p><p>Early and more intensive treatment does not clearly improve neuropsychiatric disability, which can occur even while motor symptoms have resolved [<a href="#rid48">48,50</a>]. Sleep problems and associated rage attacks may respond to <a class="drug drug_general" data-topicid="10013" href="/d/drug information/10013.html" rel="external">trazodone</a> [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H24047696"><span class="h1">ADULT SYNDROME</span></p><p class="headingAnchor" id="H6361449"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>OMAS in adults may be paraneoplastic or idiopathic in origin. An underlying cancer is found in approximately 20 to 40 percent of cases [<a href="#rid11">11,52-54</a>]. Patients with idiopathic OMAS tend to be younger than patients with paraneoplastic OMAS (mean age 40 versus 55 years) [<a href="#rid11">11,53</a>]. An exception is patients with ovarian teratoma, who often present before age 30 years [<a href="#rid11">11</a>].</p><p>The most frequent tumor associated with OMAS in adults is small cell lung cancer (SCLC) [<a href="#rid11">11,12</a>]. Other tumors have been reported, including non-small cell lung cancer, breast cancer, ovarian teratoma and other gynecologic cancers, gastric adenocarcinoma, malignant melanoma, and bladder cancer [<a href="#rid11">11,53,55-61</a>].</p><p>Most cases of paraneoplastic OMAS in adults are not associated with well-characterized antibodies [<a href="#rid11">11</a>]. An exception is a small subgroup of females with OMAS who have anti-Ri (antineuronal nuclear autoantibody type 2 [ANNA-2]) antibodies, usually in association with breast cancer (sometimes gynecologic, lung, or bladder cancers) [<a href="#rid53">53,55,56,62-64</a>]. The target antigens of anti-Ri antibodies are the Nova proteins that play a role in the regulation of synaptic proteins [<a href="#rid56">56,65</a>]. A few patients with paraneoplastic OMAS have had anti-Hu or other paraneoplastic antibodies; in such cases, these are probably nonspecific markers of underlying cancers rather than linked to OMAS [<a href="#rid12">12,53</a>].</p><p>Antibodies to neuronal surface antigens have also been reported in association with OMAS, including a small number of patients with antibodies to N-methyl-D-aspartate receptor (NMDAR), gamma-aminobutyric acid type A (GABA-A) and type B (GABA-B) receptors, dipeptidyl-peptidase-like protein-6 (DPPX), glutamic acid decarboxylase (GAD), and human natural killer 1 (HNK-1), a novel epitope contained within myelin-associated glycoprotein (MAG) as well as several other brain proteins [<a href="#rid11">11,66-68</a>]. Antibodies to the glycine receptor (GlyR) have been found in up to 20 percent of patients with lung cancer and OMAS but do not appear to be sensitive or specific for the disorder [<a href="#rid11">11</a>].</p><p>Nonparaneoplastic OMAS has been reported in adults in association with various infections, including Lyme disease [<a href="#rid69">69</a>], enterovirus [<a href="#rid70">70</a>], West Nile virus [<a href="#rid71">71</a>], Epstein-Barr virus [<a href="#rid72">72</a>], HIV [<a href="#rid73">73-75</a>], salmonella [<a href="#rid76">76</a>], cytomegalovirus [<a href="#rid77">77</a>], after anti-Rubella vaccination [<a href="#rid78">78</a>], and poststreptococcal infection [<a href="#rid79">79</a>]. Many cases of nonparaneoplastic OMAS are idiopathic and are often assumed to be para-infectious in origin [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H6361456"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>In adults, paraneoplastic OMAS often develops with truncal ataxia, resulting in gait difficulty and frequent falls [<a href="#rid53">53,54,80</a>]. Symptoms progress rapidly, leading to substantive disability within weeks.</p><p>Most patients have both myoclonus and opsoclonus on presentation; some complain of nausea and/or vomiting. Limb ataxia, tremor, and dysarthria are less frequently present. Brainstem and cerebellar signs may also be present [<a href="#rid55">55,80</a>]. Encephalopathy accompanies ocular and motor signs in 30 to 60 percent of patients with paraneoplastic OMAS and is a less frequent finding in nonparaneoplastic OMAS (10 percent) [<a href="#rid11">11,53,80</a>]. In patients with anti-Ri antibodies, opsoclonus is a frequent but not invariable finding.</p><p class="headingAnchor" id="H6361463"><span class="h2">Diagnosis in adults</span><span class="headingEndMark"> — </span>OMAS should be distinguished from other disorders that can cause similar neurologic symptoms (see <a class="local">'Differential diagnosis'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Brain imaging (MRI with gadolinium) is recommended to rule out structural lesions that can produce symptoms that may be similar to OMAS [<a href="#rid25">25</a>]. This is usually normal in OMAS, but occasionally shows hyperintensity in the dorsal pons or midbrain on T2-weighted images [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing and review of medications should be performed to exclude a toxic-metabolic encephalopathy, particularly hyperosmolar coma, liver disease, and intoxications. (See  <a class="medical medical_review" href="/d/html/1661.html" rel="external">"Acute toxic-metabolic encephalopathy in adults", section on 'Diagnosis'</a>.)</p><p></p><p>Cerebrospinal fluid (CSF) should be obtained if there is concern for acute central nervous system infection; in OMAS, this may be normal or show mild elevations of protein or mild lymphocytic pleocytosis [<a href="#rid53">53,80</a>].</p><p>Patients with OMAS who are over the age of 50 years and those with associated encephalopathy should be rigorously assessed for occult malignancy [<a href="#rid52">52</a>] (see  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Search for occult malignancy'</a>). One study identified a subset of young females (ages 15 to 32 years) who developed OMAS in association with systemic teratoma; no autoantibodies were identified, and 74 percent had a full recovery after tumor removal and immunotherapy [<a href="#rid82">82</a>].</p><p>While it is reasonable to test for paraneoplastic biomarkers, most adult patients with paraneoplastic OMAS will not test positive [<a href="#rid53">53,83</a>].</p><p>Testing for HIV should be performed if risk factors are present, as OMAS can be the initial manifestation of HIV infection or may occur during immune reconstitution at the onset of antiretroviral therapy [<a href="#rid73">73-75</a>].</p><p class="headingAnchor" id="H6361600"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Some adults with paraneoplastic OMAS have resolution of neurologic symptoms with treatment of the underlying neoplasm [<a href="#rid53">53,61</a>].</p><p>Adults may be less likely to respond to immunotherapy compared with children. Nonetheless, in uncontrolled observations, clinical responses have been reported with glucocorticoids, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG). A reasonable initial approach based largely on data in children and the knowledge that adults are at higher risk for poor outcomes is to use rituximab upfront, along with <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> with IVIG, followed by monthly pulses of steroids and IVIG while symptoms remain active. All patients should undergo appropriate tumor screening based on age and sex.</p><p>In two cases, patients responded to treatment with high doses of <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> (8 to 12 mg daily) after no response to immunotherapy [<a href="#rid84">84</a>]. Another case report describes a therapeutic response to <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> in a patient with OMAS [<a href="#rid85">85</a>].</p><p>The neurologic prognosis is better for those patients without underlying cancer and for those whose tumor is promptly diagnosed and treated than for those with untreated tumors [<a href="#rid53">53</a>]. Older adults appear to be more likely to have relapses of symptoms and residual gait ataxia [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H149647246"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117968.html" rel="external">"Society guideline links: Paraneoplastic neurologic disorders"</a>.)</p><p class="headingAnchor" id="H24048008"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare and debilitating acquired nervous system disorder characterized by opsoclonus, myoclonus, ataxia, and behavioral and sleep disturbances. Evidence supports an immune-mediated etiology, although pathogenic autoantibodies have not been identified in the majority of cases. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – OMAS usually affects young children with a mean age of 1.5 to 2 years, either as a paraneoplastic disorder in association with neuroblastoma (approximately half of cases) or as an apparent postviral syndrome. Paraneoplastic and idiopathic cases occur rarely in adults. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Adult syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients usually present with subacute ataxia manifesting as gait imbalance, staggering, and falls. Myoclonus of the limbs and trunk may appear at the same time or subsequently. Behavioral changes (irritability, crying), regression of speech and language skills, and sleep disturbances are common in children; adults may have encephalopathy.</p><p></p><p class="bulletIndent1">Although opsoclonus is characteristic of the disorder, it may not be present at initial evaluation in children and can be transient and difficult to see during examination. There are no characteristic MRI or cerebrospinal fluid (CSF) findings. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – OMAS is a clinical diagnosis based on characteristic features and exclusion of alternative etiologies through laboratories, MRI of the brain, and lumbar puncture. All children with OMAS should be evaluated for neuroblastoma; symptoms of OMAS precede the diagnosis of neuroblastoma in approximately one-half of patients. (See <a class="local">'Diagnosis in children'</a> above.)</p><p></p><p class="bulletIndent1">Adults over the age of 50 years and those with associated encephalopathy should be evaluated for occult malignancy. The most frequent tumors associated with OMAS in adults are small cell lung cancer (SCLC) and breast cancer. (See <a class="local">'Diagnosis in adults'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis in children </strong>– Immune suppression is the primary treatment for OMAS, based on the presumed autoimmune etiology, the rarity of spontaneous remissions with antitumor therapy alone, and the disabling nature of the disorder. Early initiation of therapy (eg, within two weeks of diagnosis) is believed to be associated with improved outcomes  (<a class="graphic graphic_algorithm graphicRef140814" href="/d/graphic/140814.html" rel="external">algorithm 2</a>). (See <a class="local">'Management'</a> above and <a class="local">'Tumor-directed therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy </strong>–<strong> </strong>In children with OMAS, we suggest an initial regimen of glucocorticoids plus intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), rather than glucocorticoids alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Reasonable alternative agents used at some centers include corticotropin (ACTH) instead of glucocorticoids and plasma exchange instead of IVIG. (See <a class="local">'Approach to immune suppression'</a> above and <a class="local">'Glucocorticoids'</a> above and <a class="local">'Intravenous immune globulin (IVIG)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Escalation</strong> – In children who do not show clinical improvement in the first four to eight weeks of initial therapy, we suggest adding <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> has been commonly used in the past but has greater potential toxicities. Some experts favor using rituximab or cyclophosphamide even earlier, as first-line therapy in combination with glucocorticoids and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>. (See <a class="local">'Approach to immune suppression'</a> above and <a class="local">'Rituximab'</a> above and <a class="local">'Cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy</strong> – Optimal duration of initial treatment is not known, but expert consensus favors a goal of complete symptom resolution and up to a year of immune suppression before de-escalation of therapy. (See <a class="local">'Monitoring and relapse'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prognosis</strong> – The neurologic prognosis of OMAS is guarded. Although many patients achieve partial or complete recovery of motor function with initial treatment, long-term behavioral and neurocognitive disability is common. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis in adults</strong> – Optimal treatment for adults with OMAS is unknown. It is reasonable to try multiagent immune suppression, based largely on experience in children with neuroblastoma, in addition to anticancer therapy, as indicated. (See <a class="local">'Treatment and prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 2010; 14:156.</a></li><li><a class="nounderline abstract_t">Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005; 22:8.</a></li><li><a class="nounderline abstract_t">Hasegawa S, Matsushige T, Kajimoto M, et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev 2015; 37:656.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children. Pediatr Blood Cancer 2018; 65:e27097.</a></li><li><a class="nounderline abstract_t">Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36:612.</a></li><li><a class="nounderline abstract_t">Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 2000; 22:315.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Travelstead AL, Tate ED, et al. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord 2004; 19:770.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, McGee NR, Tate ED. Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS. J Neuroimmunol 2018; 321:150.</a></li><li><a class="nounderline abstract_t">Connolly AM, Pestronk A, Mehta S, et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues. J Pediatr 1997; 130:878.</a></li><li><a class="nounderline abstract_t">Blaes F, Fühlhuber V, Korfei M, et al. Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol 2005; 58:313.</a></li><li><a class="nounderline abstract_t">Armangué T, Sabater L, Torres-Vega E, et al. Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol 2016; 73:417.</a></li><li><a class="nounderline abstract_t">Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003; 53:347.</a></li><li><a class="nounderline abstract_t">Panzer JA, Anand R, Dalmau J, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol 2015; 286:86.</a></li><li><a class="nounderline abstract_t">Ertekin V, Tan H. Opsoclonus-myoclonus syndrome attributable to hepatitis C infection. Pediatr Neurol 2010; 42:441.</a></li><li><a class="nounderline abstract_t">Vukelic D, Bozinovic D, Morovic M, et al. Opsoclonus-myoclonus syndrome in a child with neuroborreliosis. J Infect 2000; 40:189.</a></li><li><a class="nounderline abstract_t">Cardesa-Salzmann TM, Mora J, García Cazorla MA, et al. Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. Pediatr Blood Cancer 2006; 47:964.</a></li><li><a class="nounderline abstract_t">Sheth RD, Horwitz SJ, Aronoff S, et al. Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection. J Child Neurol 1995; 10:297.</a></li><li><a class="nounderline abstract_t">Candler PM, Dale RC, Griffin S, et al. Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies. J Neurol Neurosurg Psychiatry 2006; 77:507.</a></li><li><a class="nounderline abstract_t">van Toorn R, Rabie H, Warwick JM. Opsoclonus-myoclonus in an HIV-infected child on antiretroviral therapy--possible immune reconstitution inflammatory syndrome. Eur J Paediatr Neurol 2005; 9:423.</a></li><li><a class="nounderline abstract_t">Kuban KC, Ephros MA, Freeman RL, et al. Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection. Ann Neurol 1983; 13:69.</a></li><li><a class="nounderline abstract_t">Huber BM, Strozzi S, Steinlin M, et al. Mycoplasma pneumoniae associated opsoclonus-myoclonus syndrome in three cases. Eur J Pediatr 2010; 169:441.</a></li><li><a class="nounderline abstract_t">Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005; 228:275.</a></li><li><a class="nounderline abstract_t">Wells EM, Dalmau J. Paraneoplastic neurologic disorders in children. Curr Neurol Neurosci Rep 2011; 11:187.</a></li><li><a class="nounderline abstract_t">Rossor T, Yeh EA, Khakoo Y, et al. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective. Neurol Neuroimmunol Neuroinflamm 2022; 9.</a></li><li><a class="nounderline abstract_t">Wong A. An update on opsoclonus. Curr Opin Neurol 2007; 20:25.</a></li><li><a class="nounderline abstract_t">Anand G, Bridge H, Rackstraw P, et al. Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. Dev Med Child Neurol 2015; 57:265.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 2002; 27:384.</a></li><li><a class="nounderline abstract_t">Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008; 28:58.</a></li><li><a class="nounderline abstract_t">Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr 2001; 139:552.</a></li><li><a class="nounderline abstract_t">Saini L, Dhawan SR, Madaan P, et al. Infection-Associated Opsoclonus: A Retrospective Case Record Analysis and Review of Literature. J Child Neurol 2020; 35:480.</a></li><li><a class="nounderline abstract_t">Desai J, Mitchell WG. Acute cerebellar ataxia, acute cerebellitis, and opsoclonus-myoclonus syndrome. J Child Neurol 2012; 27:1482.</a></li><li><a class="nounderline abstract_t">De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009; 40:103.</a></li><li><a class="nounderline abstract_t">Hammer MS, Larsen MB, Stack CV. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol 1995; 13:21.</a></li><li><a class="nounderline abstract_t">Mitchell WG, Snodgrass SR. Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome. J Child Neurol 1990; 5:153.</a></li><li><a class="nounderline abstract_t">de Alarcon PA, Matthay KK, London WB, et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health 2018; 2:25.</a></li><li><a class="nounderline abstract_t">Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28:284.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, Kinsbourne M, et al. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG. Mov Disord 2002; 17:1387.</a></li><li><a class="nounderline abstract_t">Rostásy K, Wilken B, Baumann M, et al. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome. Neuropediatrics 2006; 37:291.</a></li><li><a class="nounderline abstract_t">Wilken B, Baumann M, Bien CG, et al. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol 2008; 12:51.</a></li><li><a class="nounderline abstract_t">Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr 2007; 166:359.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, Travelstead AL, et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol 2009; 24:316.</a></li><li><a class="nounderline abstract_t">Ertle F, Behnisch W, Al Mulla NA, et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr Blood Cancer 2008; 50:683.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28:585.</a></li><li><a class="nounderline abstract_t">Tate ED, Pranzatelli MR, Verhulst SJ, et al. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome. J Child Neurol 2012; 27:875.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome. Pediatr Neurol 2017; 73:48.</a></li><li><a class="nounderline abstract_t">Wilbur C, Yea C, Licht C, et al. An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome. Pediatr Blood Cancer 2019; 66:e27776.</a></li><li><a class="nounderline abstract_t">Patel A, Fischer C, Lin YC, et al. Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience. Pediatr Blood Cancer 2020; 67:e28319.</a></li><li><a class="nounderline abstract_t">Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109:86.</a></li><li><a class="nounderline abstract_t">Krug P, Schleiermacher G, Michon J, et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010; 14:400.</a></li><li><a class="nounderline abstract_t">Catsman-Berrevoets CE, Aarsen FK, van Hemsbergen ML, et al. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up. Pediatr Blood Cancer 2009; 53:1048.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, Dukart WS, et al. Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone. J Pediatr 2005; 147:372.</a></li><li><a class="nounderline abstract_t">Digre KB. Opsoclonus in adults. Report of three cases and review of the literature. Arch Neurol 1986; 43:1165.</a></li><li><a class="nounderline abstract_t">Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124:437.</a></li><li><a class="nounderline abstract_t">Klaas JP, Ahlskog JE, Pittock SJ, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol 2012; 69:1598.</a></li><li><a class="nounderline abstract_t">Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29:241.</a></li><li><a class="nounderline abstract_t">Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996; 16:1114.</a></li><li><a class="nounderline abstract_t">Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53:580.</a></li><li><a class="nounderline abstract_t">Fitzpatrick AS, Gray OM, McConville J, McDonnell GV. Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma. Neurology 2008; 70:1292.</a></li><li><a class="nounderline abstract_t">Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol 2006; 253:942.</a></li><li><a class="nounderline abstract_t">Kawachi I, Saji E, Toyoshima Y, et al. Treatment responsive opsoclonus-ataxia associated with ovarian teratoma. J Neurol Neurosurg Psychiatry 2010; 81:581.</a></li><li><a class="nounderline abstract_t">Erlich R, Morrison C, Kim B, et al. ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response. Cancer Invest 2004; 22:257.</a></li><li><a class="nounderline abstract_t">Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993; 43:207.</a></li><li><a class="nounderline abstract_t">Lewis MA, Hartmann LC, Lachance DH, Jimenez RE. Opsoclonus as a suspected paraneoplastic syndrome of endometrial cancer. Rare Tumors 2010; 2:e42.</a></li><li><a class="nounderline abstract_t">Weizman DA, Leong WL. Anti-Ri antibody opsoclonus-myoclonus syndrome and breast cancer: a case report and a review of the literature. J Surg Oncol 2004; 87:143.</a></li><li><a class="nounderline abstract_t">Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci U S A 1998; 95:13254.</a></li><li><a class="nounderline abstract_t">DeFelipe-Mimbrera A, Masjuan J, Corral Í, et al. Opsoclonus-myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF. J Neuroimmunol 2014; 272:91.</a></li><li><a class="nounderline abstract_t">Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13:276.</a></li><li><a class="nounderline abstract_t">Markakis I, Alexiou E, Xifaras M, et al. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg 2008; 110:619.</a></li><li><a class="nounderline abstract_t">Peter L, Jung J, Tilikete C, et al. Opsoclonus-myoclonus as a manifestation of Lyme disease. J Neurol Neurosurg Psychiatry 2006; 77:1090.</a></li><li><a class="nounderline abstract_t">Wiest G, Safoschnik G, Schnaberth G, Mueller C. Ocular flutter and truncal ataxia may be associated with enterovirus infection. J Neurol 1997; 244:288.</a></li><li><a class="nounderline abstract_t">Alshekhlee A, Sultan B, Chandar K. Opsoclonus persisting during sleep in West Nile encephalitis. Arch Neurol 2006; 63:1324.</a></li><li><a class="nounderline abstract_t">Verma A, Brozman B. Opsoclonus-myoclonus syndrome following Epstein-Barr virus infection. Neurology 2002; 58:1131.</a></li><li><a class="nounderline abstract_t">Kanjanasut N, Phanthumchinda K, Bhidayasiri R. HIV-related opsoclonus-myoclonus-ataxia syndrome: report on two cases. Clin Neurol Neurosurg 2010; 112:572.</a></li><li><a class="nounderline abstract_t">Scott KM, Parker F, Heckmann JM. Opsoclonus-myoclonus syndrome and HIV-infection. J Neurol Sci 2009; 284:192.</a></li><li><a class="nounderline abstract_t">Ayarza A, Parisi V, Altclas J, et al. Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion. J Neurol 2009; 256:1024.</a></li><li><a class="nounderline abstract_t">Flabeau O, Meissner W, Foubert-Samier A, et al. Opsoclonus myoclonus syndrome in the context of Salmonellosis. Mov Disord 2009; 24:2306.</a></li><li><a class="nounderline abstract_t">Zaganas I, Prinianakis G, Xirouchaki N, Mavridis M. Opsoclonus-myoclonus syndrome associated with cytomegalovirus encephalitis. Neurology 2007; 68:1636.</a></li><li><a class="nounderline abstract_t">Lapenna F, Lochi L, de Mari M, et al. Post-vaccinic opsoclonus-myoclonus syndrome: a case report. Parkinsonism Relat Disord 2000; 6:241.</a></li><li><a class="nounderline abstract_t">Dassan P, Clarke C, Sharp DJ. A case of poststreptococcal opsoclonus-myoclonus syndrome. Mov Disord 2007; 22:1490.</a></li><li><a class="nounderline abstract_t">Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) 1988; 67:100.</a></li><li><a class="nounderline abstract_t">Hormigo A, Dalmau J, Rosenblum MK, et al. Immunological and pathological study of anti-Ri-associated encephalopathy. Ann Neurol 1994; 36:896.</a></li><li><a class="nounderline abstract_t">Armangue T, Titulaer MJ, Sabater L, et al. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 2014; 75:435.</a></li><li><a class="nounderline abstract_t">Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327.</a></li><li><a class="nounderline abstract_t">Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol 2006; 56:240.</a></li><li><a class="nounderline abstract_t">Fernandes TD, Bazan R, Betting LE, da Rocha FC. Topiramate effect in opsoclonus-myoclonus-ataxia syndrome. Arch Neurol 2012; 69:133.</a></li></ol></div><div id="topicVersionRevision">Topic 15861 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19423368" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15574722" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25454391" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29727049" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multifactorial analysis of opsoclonus-myoclonus syndrome etiology ("Tumor" vs. "No tumor") in a cohort of 356 US children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344492" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959901" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254934" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29685330" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9202608" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15988749" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26856612" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12601702" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Autoantigen diversity in the opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26298330" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472199" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Opsoclonus-myoclonus syndrome attributable to hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841099" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Opsoclonus-myoclonus syndrome in a child with neuroborreliosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16200567" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7594265" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Opsoclonus myoclonus syndrome secondary to Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543530" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269259" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Opsoclonus-myoclonus in an HIV-infected child on antiretroviral therapy--possible immune reconstitution inflammatory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6299176" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Syndrome of opsoclonus-myoclonus caused by Coxsackie B3 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19774394" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mycoplasma pneumoniae associated opsoclonus-myoclonus syndrome in three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15922508" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21161703" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Paraneoplastic neurologic disorders in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35260471" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215685" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An update on opsoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25290446" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12504207" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347462" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neuro-ophthalmologic manifestations of paraneoplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598603" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32216501" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Infection-Associated Opsoclonus: A Retrospective Case Record Analysis and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805251" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acute cerebellar ataxia, acute cerebellitis, and opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20020394" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575843" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outcome of children with opsoclonus-myoclonus regardless of etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2345282" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Opsoclonus-ataxia due to childhood neural crest tumors: a chronic neurologic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29376112" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078325" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12465092" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Forty-one year follow-up of childhood-onset opsoclonus-myoclonus-ataxia: cerebellar atrophy, multiphasic relapses, and response to IVIG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17236108" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17625938" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17089089" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term outcome of ten children with opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258290" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17226843" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17006265" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22378659" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28651977" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31033188" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32543116" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment and revaccination of children with paraneoplastic opsoclonus-myoclonus-ataxia syndrome and neuroblastoma: The Memorial Sloan Kettering experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773546" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20110181" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Opsoclonus-myoclonus in children associated or not with neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19672966" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182678" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sleep disturbance and rage attacks in opsoclonus-myoclonus syndrome: response to trazodone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3535750" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Opsoclonus in adults. Report of three cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157570" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22986354" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Adult-onset opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2042940" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558240" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730991" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391162" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16715202" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Opsoclonus-myoclonus syndrome in an adult with malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460596" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment responsive opsoclonus-ataxia associated with ovarian teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15199608" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8423887" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21139958" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Opsoclonus as a suspected paraneoplastic syndrome of endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334643" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Anti-Ri antibody opsoclonus-myoclonus syndrome and breast cancer: a case report and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9789075" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24814391" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Opsoclonus-myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462240" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433986" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914760" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Opsoclonus-myoclonus as a manifestation of Lyme disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9178152" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ocular flutter and truncal ataxia may be associated with enterovirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966514" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Opsoclonus persisting during sleep in West Nile encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940712" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Opsoclonus-myoclonus syndrome following Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427123" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : HIV-related opsoclonus-myoclonus-ataxia syndrome: report on two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19419738" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Opsoclonus-myoclonus syndrome and HIV-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252789" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Opsoclonus-myoclonus-ataxia syndrome and HIV seroconversion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845009" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Opsoclonus myoclonus syndrome in the context of Salmonellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485656" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Opsoclonus-myoclonus syndrome associated with cytomegalovirus encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10900400" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Post-vaccinic opsoclonus-myoclonus syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17486621" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A case of poststreptococcal opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3352511" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7998777" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Immunological and pathological study of anti-Ri-associated encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23613036" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339348" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Paraneoplastic syndromes of the CNS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17057386" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232356" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Topiramate effect in opsoclonus-myoclonus-ataxia syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
